Physician profile
Bilal Khan
NPI 1013330091
$3,680.69
in general payments reported to CMS, 2019-2025
21 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $234 · 2021: $766 · 2022: $449 · 2023: $787 · 2024: $421 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $716.65 | 2020-2024 | Andexxa, Fasenra |
| Shionogi INC | $629.10 | 2022-2025 | Fetroja |
| Abbvie INC. | $420.16 | 2021-2025 | |
| Chiesi USA, INC. | $374.78 | 2021-2025 | Cleviprex, Kengreal |
| Boston Scientific Corporation | $319.76 | 2019 | |
| La Jolla Pharmaceutical Company | $238.30 | 2021-2024 | Giapreza |
| Gilead Sciences, INC. | $221.41 | 2023-2024 | Veklury |
| Csl Behring | $186.10 | 2020-2023 | Kcentra |
| Mallinckrodt Hospital Products INC. | $105.10 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $88.56 | 2022-2025 | Zerbaxa, Recarbrio |
| Inari Medical, INC. | $71.76 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alexion Pharmaceuticals, INC. | $61.49 | 2022-2023 | Ultomiris |
| Janssen Pharmaceuticals, INC | $49.38 | 2020-2024 | Xarelto |
| Mindray Ds USA, INC. | $43.87 | 2022 | |
| Melinta Therapeutics, LLC | $39.62 | 2022-2023 | Kimyrsa, Rezzayo, Vabomere |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $33.20 | 2021-2022 | |
| Insmed, INC. | $19.70 | 2025 | Arikayce |
| Lilly USA, LLC | $19.45 | 2024 | |
| Philips North America LLC | $14.63 | 2022 | |
| Heron Therapeutics, INC. | $14.18 | 2025 | Aponvie |
| Daiichi Sankyo INC. | $13.49 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.